For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Avidity Biosciences Inc (NASDAQ: RNA) closed at $48.26 in the last session, up 2.79% from day before closing price of $46.95. In other words, the price has increased by $2.79 from its previous closing price. On the day, 1.15 million shares were traded. RNA stock price reached its highest trading level at $49.48 during the session, while it also had its lowest trading level at $46.59.
Ratios:
We take a closer look at RNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.26 and its Current Ratio is at 9.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Roth Capital on September 17, 2025, initiated with a Buy rating and assigned the stock a target price of $62.
On June 24, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $50.Bernstein initiated its Outperform rating on June 24, 2025, with a $50 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 03 ’25 when Mosbrooker Eric sold 6,562 shares for $45.38 per share. The transaction valued at 297,771 led to the insider holds 55,000 shares of the business.
Hughes Steven George sold 2,208 shares of RNA for $89,601 on Sep 22 ’25. The Chief Medical Officer now owns 38,867 shares after completing the transaction at $40.58 per share. On Sep 15 ’25, another insider, McCarthy Teresa, who serves as the Chief Human Resources Officer of the company, sold 15,000 shares for $41.41 each. As a result, the insider received 621,142 and left with 97,130 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 7041295360 and an Enterprise Value of 5030800896. For the stock, the TTM Price-to-Sale (P/S) ratio is 656.22 while its Price-to-Book (P/B) ratio in mrq is 4.89. Its current Enterprise Value per Revenue stands at 468.897 whereas that against EBITDA is -9.698.
Stock Price History:
The Beta on a monthly basis for RNA is 0.92, which has changed by 0.0913614 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 8.91%, while the 200-Day Moving Average is calculated to be 41.42%.
Shares Statistics:
According to the various share statistics, RNA traded on average about 3.34M shares per day over the past 3-months and 1801660 shares per day over the past 10 days. A total of 145.90M shares are outstanding, with a floating share count of 131.53M. Insiders hold about 9.85% of the company’s shares, while institutions hold 91.01% stake in the company. Shares short for RNA as of 1757894400 were 22242546 with a Short Ratio of 6.67, compared to 1755216000 on 15671917. Therefore, it implies a Short% of Shares Outstanding of 22242546 and a Short% of Float of 15.359998999999998.
Earnings Estimates
Avidity Biosciences Inc (RNA) is currently under the scrutiny of 15.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$1.27, with high estimates of -$0.61 and low estimates of -$2.36.
Analysts are recommending an EPS of between -$3.33 and -$6.26 for the fiscal current year, implying an average EPS of -$4.49. EPS for the following year is -$4.97, with 16.0 analysts recommending between -$3.24 and -$7.31.
